Melnyk, James E. http://orcid.org/0000-0003-1915-8089
Steri, Veronica
Nguyen, Hao G.
Hwang, Y. Christina http://orcid.org/0000-0002-3000-4710
Gordan, John D. http://orcid.org/0000-0001-8997-5725
Hann, Byron
Feng, Felix Y. http://orcid.org/0000-0002-0963-7687
Shokat, Kevan M. http://orcid.org/0000-0001-8590-7741
Article History
Received: 25 August 2021
Revised: 14 December 2021
Accepted: 5 January 2022
First Online: 27 January 2022
Competing interests
: KMS has consulting agreements for the following companies involving cash and/or stock compensation: Black Diamond Therapeutics, BridGene Biosciences, Denali Therapeutics, eFFECTOR Therapeutics, Erasca, Genentech/Roche, Janssen Pharmaceuticals, Kumquat Biosciences, Kura Oncology, Merck, Mitokinin, Petra Pharma, Revolution Medicines, Type6 Therapeutics, Venthera, Wellspring Biosciences (Araxes Pharma). FYF has received consulting fees from Astellas, Bayer, Blue Earth Diagnostics, Celgene, Genentech, Janssen, Myovant, Roivant, and Sanofi. No potential conflicts of interest were disclosed by the other authors.